Skip to content

Effect of ustukhuddoos (unani single drug) in paralysis on one side of the body

Effect of Ustukhuddoos on motor function & quality of life in subject with residual hemiplegia - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079267
Enrollment
58
Registered
2025-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G00-G99- Diseases of the nervous system

Interventions

Intervention1: Unani drug Ustukhuddoos: 7g of ustukhuddoos in powder form will be given orally twice a day for 2 months Control Intervention1: Wheat flour: Wheat flour will be used as a placebo contro

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient must have had an ischemic vascular lesion i.e, stroke as documented by computerized tomography or magnetic resonance imaging. Neurologically and medically stable patients as determined by medical history and documented neurological examination. Score on the UE-FM of greater than 28 to less than 51 and active extension in the affected wrist of at least 50 Score on the lower limb FMA-LE score less than 34 Age more than 21 years at time of enrolment. Patients having a history of stroke occur more than 2 months prior to study enrolment. Either gender

Exclusion criteria

Exclusion criteria: Hemorrhagic stroke more than 1 stroke Any neurologic conditions (beyond the stroke) or physical conditions that impaired functions of the affected extremities. History of seizure disorders or spontaneous seizures that had occurred 1 month or longer after the stroke. History of Serious neurological conditions including central nervous system vasculitis, intracranial tumor, intracranial aneurism, multiple sclerosis, or arteriovenous malformations. History of Severe sensory deficit. Inability to understand, cooperate, and adhere to the study procedure. History of spinal cord injury, brain injury, or spontaneous subdural or epidural hematoma that has resulted in neurologic deficit History of potentially fatal cardiac arrhythmia. COPD Uncontrolled Diabetes and Hypertension. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Improvement in grip strength, Range of Motion, Spasticity or motor power ,Gait & SpeedTimepoint: at baseline, 30th, 60th day

Secondary

MeasureTime frame
Assessment of Efficacy Lipid profile & quality of lifeTimepoint: at baseline &b 60th day

Countries

India

Contacts

Public ContactNishat Rao

NATIONAL INSTITUTE OF UNANI MEDICINE, BANGALORE-91

kzarnigar15@gmail.com7483244027

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026